Nuwellis Inc. logo

Nuwellis Inc. (NUWE)

Market Closed
12 Dec, 20:00
NASDAQ (CM) NASDAQ (CM)
$
2. 28
-0.17
-6.94%
$
2.18M Market Cap
0.02 P/E Ratio
0% Div Yield
60,857 Volume
-12.19 Eps
$ 2.45
Previous Close
Day Range
2.24 2.58
Year Range
2.02 70.14
Want to track NUWE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

NUWE closed Friday lower at $2.28, a decrease of 6.94% from Thursday's close, completing a monthly decrease of -2.15% or $0.05. Over the past 12 months, NUWE stock lost -95.51%.
NUWE is not paying dividends to its shareholders.
The last earnings report, released on Nov 12, 2025, exceeded the consensus estimates by 0.56%. On average, the company has surpassed earnings expectations by 0.34%, based on the last three reports.
Nuwellis Inc. has completed 8 stock splits, with the recent split occurring on Jul 07, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

NUWE Chart

Similar

Cytosorbents Corporation
$ 0.65
-8.87%
Kalaris Therapeutics, Inc.
$ 9.81
+4.14%
CUE
Cue Biopharma Inc.
$ 0.48
-2.27%
Spectral AI Inc.
$ 1.6
-6.69%
IceCure Medical Ltd.
$ 0.67
-3.5%
Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Prepared Remarks Transcript

Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Prepared Remarks Transcript

Nuwellis, Inc. ( NUWE ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Leah McMullen - Director of Communications John Erb - Interim CFO, Interim Principal Financial & Accounting Officer, CEO, President and Chairman Lynn Blake Presentation Operator Good day, everyone, and welcome to today's Nuwellis Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, today's call will be recorded, and I will be standing by should you need any assistance.

Seekingalpha | 1 month ago
Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript

Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript

Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2025 Earnings Conference Call August 14, 2025 9:00 AM ET Company Participants John L. Erb - CEO, President & Chairman of the Board Leah McMullen - Corporate Participant Robert B.

Seekingalpha | 4 months ago
Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript

Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript

Nuwellis, Inc. (NASDAQ:NUWE ) Q1 2025 Earnings Conference Call May 13, 2025 9:00 AM ET Company Participants Louisa Smith - IR, Gilmartin Group John Erb - Chairman & Interim CEO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - ROTH Operator Good day, everyone, and welcome to Nuwellis First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Seekingalpha | 7 months ago

Nuwellis Inc. (NUWE) FAQ

What is the stock price today?

The current price is $2.28.

On which exchange is it traded?

Nuwellis Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is NUWE.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 2.18M.

Has Nuwellis Inc. ever had a stock split?

Nuwellis Inc. had 8 splits and the recent split was on Jul 07, 2025.

Nuwellis Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
John L. Erb CEO
NASDAQ (CM) Exchange
67113Y702 CUSIP
US Country
38 Employees
- Last Dividend
13 Oct 2017 Last Split
16 Feb 2012 IPO Date

Overview

Nuwellis, Inc. is a pioneering medical device company that specializes in the development, manufacture, and commercialization of unique devices designed for ultrafiltration therapy. Founded in 1999 and initially known as CHF Solutions, Inc., the company rebranded itself as Nuwellis, Inc. in April 2021. With its headquarters in Eden Prairie, Minnesota, Nuwellis has carved a niche in aiding patients who suffer from fluid overload, a condition often associated with heart failure. The company's reach extends beyond the United States, with its products being available through direct sales forces and independent specialty distributors across various countries including Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.

Products and Services

  • Aquadex FlexFlow System

This comprehensive system, a cornerstone of Nuwellis’ products, was designed with the aim of treating patients grappling with fluid overload due to heart failure. The Aquadex FlexFlow system includes a console, a disposable blood circuit set, and a disposable catheter, each component playing a crucial role in the ultrafiltration process. By removing excess fluid from patients, this system helps in alleviating symptoms and improving quality of life.

  • Aquadex SmartFlow System

The Aquadex SmartFlow system represents the evolution in the domain of ultrafiltration therapy by Nuwellis. Although detailed specifics of its features compared to the FlexFlow system aren't outlined here, the naming suggests advancements or improvements aimed at enhancing the efficacy or user-friendliness of the ultrafiltration process. This system, like its predecessor, is targeted at patients suffering from severe fluid overload due to heart failure, underscoring the company's commitment to innovating and improving patient care in this area.

Contact Information

Address: 12988 Valley View Road
Phone: 952 345 4200